[{"id":"de0eb004-7071-4d0b-b9a0-5aa41fe0d166","acronym":"PInNACLe","url":"https://clinicaltrials.gov/study/NCT02001818","created_at":"2021-01-18T09:08:24.888Z","updated_at":"2025-02-25T15:41:09.436Z","phase":"Phase 2","brief_title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","source_id_and_acronym":"NCT02001818 - PInNACLe","lead_sponsor":"Australasian Leukaemia and Lymphoma Group","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/11/2014","start_date":" 04/11/2014","primary_txt":" Primary completion: 01/07/2022","primary_completion_date":" 01/07/2022","study_txt":" Completion: 01/07/2022","study_completion_date":" 01/07/2022","last_update_posted":"2024-08-06"},{"id":"d886936b-36f5-4752-8f4f-80f034f5322b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00574730","created_at":"2021-01-18T02:05:56.207Z","updated_at":"2025-02-25T15:57:28.177Z","phase":"","brief_title":"CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00574730","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 05/23/2001","start_date":" 05/23/2001","primary_txt":" Primary completion: 08/01/2005","primary_completion_date":" 08/01/2005","study_txt":" Completion: 06/07/2012","study_completion_date":" 06/07/2012","last_update_posted":"2023-09-14"},{"id":"c19a421c-ad6d-45d9-80b4-19d5d1e7f713","acronym":"KEYNOTE 029","url":"https://clinicaltrials.gov/study/NCT02089685","created_at":"2022-05-19T03:53:45.408Z","updated_at":"2024-07-02T16:36:04.100Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)","source_id_and_acronym":"NCT02089685 - KEYNOTE 029","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 295","initiation":"Initiation: 03/17/2014","start_date":" 03/17/2014","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2021","study_completion_date":" 04/01/2021","last_update_posted":"2022-09-13"},{"id":"32d03e17-4e21-4018-9115-6e673993800d","acronym":"VEMUPLINT","url":"https://clinicaltrials.gov/study/NCT01959633","created_at":"2021-01-17T17:17:19.936Z","updated_at":"2024-07-02T16:36:16.667Z","phase":"Phase 1/2","brief_title":"Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation","source_id_and_acronym":"NCT01959633 - VEMUPLINT","lead_sponsor":"Fondazione Melanoma Onlus","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Cotellic (cobimetinib) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/03/2014","start_date":" 04/03/2014","primary_txt":" Primary completion: 03/26/2018","primary_completion_date":" 03/26/2018","study_txt":" Completion: 03/26/2018","study_completion_date":" 03/26/2018","last_update_posted":"2022-02-24"},{"id":"1a07d589-e503-42cc-bbbb-4d45030df1ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02379195","created_at":"2021-01-18T11:20:00.199Z","updated_at":"2024-07-02T16:36:51.037Z","phase":"Phase 1/2","brief_title":"Peginterferon and TIL Therapy for Metastatic Melanoma","source_id_and_acronym":"NCT02379195","lead_sponsor":"Inge Marie Svane","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • ViraferonPeg (peginterferon-α-2b) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2020-01-22"},{"id":"3629edc5-f527-4087-a4f7-97f634c0b8f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01544920","created_at":"2022-07-18T07:54:24.897Z","updated_at":"2024-07-02T16:37:07.027Z","phase":"Phase 3","brief_title":"Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)","source_id_and_acronym":"NCT01544920","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" IFNL3","pipe":"","alterations":" ","tags":["IFNL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pegasys (pegylated interferon α -2a) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 737","initiation":"Initiation: 05/30/2012","start_date":" 05/30/2012","primary_txt":" Primary completion: 05/19/2015","primary_completion_date":" 05/19/2015","study_txt":" Completion: 05/19/2015","study_completion_date":" 05/19/2015","last_update_posted":"2018-09-11"},{"id":"c348c65a-870f-40cf-88ec-7ac6203600f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00678951","created_at":"2021-01-18T02:32:16.777Z","updated_at":"2024-07-02T16:37:16.654Z","phase":"Phase 2","brief_title":"Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults","source_id_and_acronym":"NCT00678951","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-11-06"},{"id":"f2e641f4-5aa8-4988-8818-2ec0a4718aa3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00396019","created_at":"2021-01-18T01:23:00.917Z","updated_at":"2024-07-02T16:37:16.587Z","phase":"Phase 2","brief_title":"Study of PEG-Intron for Plexiform Neurofibromas","source_id_and_acronym":"NCT00396019","lead_sponsor":"University of Pittsburgh","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 12/01/2006","start_date":" 12/01/2006","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2017-11-06"},{"id":"b94011db-053b-47ae-9c01-264107c289cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01496807","created_at":"2021-01-18T06:16:24.075Z","updated_at":"2025-02-25T16:02:11.159Z","phase":"Phase 1","brief_title":"Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma","source_id_and_acronym":"NCT01496807","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 02/17/2012","start_date":" 02/17/2012","primary_txt":" Primary completion: 03/16/2016","primary_completion_date":" 03/16/2016","study_txt":" Completion: 08/29/2016","study_completion_date":" 08/29/2016","last_update_posted":"2017-04-28"},{"id":"bae963e4-cf50-4606-a61b-3d77d2ae9a7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00759109","created_at":"2021-01-18T02:52:04.305Z","updated_at":"2024-07-02T16:37:23.658Z","phase":"Phase 3","brief_title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","source_id_and_acronym":"NCT00759109","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" AFP • PCNA","pipe":"","alterations":" ","tags":["AFP • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 03/01/2002","start_date":" 03/01/2002","primary_txt":" Primary completion: 11/01/2009","primary_completion_date":" 11/01/2009","study_txt":" Completion: 11/01/2009","study_completion_date":" 11/01/2009","last_update_posted":"2017-04-07"},{"id":"2cfb63f8-caef-4e92-b1d4-4723a0502155","acronym":"","url":"https://clinicaltrials.gov/study/NCT01463956","created_at":"2021-10-27T14:53:03.432Z","updated_at":"2025-02-25T16:02:01.047Z","phase":"Phase 2","brief_title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","source_id_and_acronym":"NCT01463956","lead_sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","biomarkers":" IFNL3 • ITPA","pipe":"","alterations":" ","tags":["IFNL3 • ITPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 01/06/2012","start_date":" 01/06/2012","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 01/22/2015","study_completion_date":" 01/22/2015","last_update_posted":"2017-01-24"},{"id":"00c80baa-e936-4958-a5aa-2b8e676204c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01838772","created_at":"2021-01-18T08:11:20.456Z","updated_at":"2024-07-02T16:37:28.161Z","phase":"Phase 4","brief_title":"HCV Treatment in HIV Co-Infected Patients in Asia","source_id_and_acronym":"NCT01838772","lead_sponsor":"amfAR, The Foundation for AIDS Research","biomarkers":" AFP • CD4","pipe":"","alterations":" ","tags":["AFP • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 188","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2016-10-27"},{"id":"99af91f7-a186-47e0-a42f-ee5ddd39007a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00050531","created_at":"2021-01-18T00:05:24.448Z","updated_at":"2025-02-25T15:47:04.247Z","phase":"Phase 3","brief_title":"High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)","source_id_and_acronym":"NCT00050531","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Leukine (sargramostim) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 04/01/2003","start_date":" 04/01/2003","primary_txt":" Primary completion: 04/01/2007","primary_completion_date":" 04/01/2007","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2016-05-11"}]